Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.,Oncogene

当前位置： X-MOL 学术 › Oncogene › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.
Oncogene ( IF 6.9 ) Pub Date : 2019-12-04 , DOI: 10.1038/s41388-019-1124-8
Panagiota S Filippou _{1,

2} , George S Karagiannis _{3,

4,

5} , Anastasia Constantinidou _{6,

7,

8}

Affiliation

Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration, and angiogenesis. Several studies have investigated the role of midkine as a cancer biomarker for the detection, prognosis, and management of cancer, as well as for monitoring the response to cancer treatment. Moreover, several efforts are also being made to elucidate its underlying mechanisms in therapeutic resistance and immunomodulation within the tumor microenvironment. We hereby summarize the current knowledge on midkine expression and function in cancer development and progression, and highlight its promising potential as a cancer biomarker and as a future therapeutic target in personalized cancer medicine.

中文翻译：

Midkine (MDK) 生长因子：癌症进展的关键参与者和有希望的治疗靶点。

Midkine 是一种肝素结合生长因子，最初报道为胚胎发生过程中视黄酸反应基因的产物，但目前被视为有助于正常组织稳态和疾病发展的多方面因素。Midkine 在各种人类恶性肿瘤中异常高水平表达，并充当获得癌症关键标志的介质，包括细胞生长、存活、转移、迁移和血管生成。几项研究调查了中期因子作为癌症生物标志物在癌症检测、预后和管理以及监测对癌症治疗的反应方面的作用。此外，还正在进行一些努力来阐明其在肿瘤微环境中的治疗抗性和免疫调节的潜在机制。

更新日期：2019-12-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11